首页 | 本学科首页   官方微博 | 高级检索  
检索        

舒尼替尼调控miR-143对人肾癌细胞增殖、侵袭的影响
引用本文:高迎新,应冲涛,崔迪,梅传忠.舒尼替尼调控miR-143对人肾癌细胞增殖、侵袭的影响[J].蚌埠医学院学报,2021,46(5):566-569.
作者姓名:高迎新  应冲涛  崔迪  梅传忠
作者单位:1.蚌埠医学院 临床检验诊断学实验中心, 安徽 蚌埠 2330302.安徽省蚌埠市第三人民医院 检验科, 2330003.蚌埠医学院 生物化学与分子生物学教研室, 安徽 蚌埠 233030
摘    要:目的探讨miR-143在肾癌细胞中的作用、舒尼替尼对miR-143表达的影响及与细胞增殖、侵袭的关系。方法培养人肾癌786-O细胞株,分为对照组、miR-143组、舒尼替尼组、共同作用组。对照组细胞转染阴性对照序列,miR-143组细胞转染miR-143序列,舒尼替尼组细胞用舒尼替尼处理48 h,共同作用组细胞转染miR-143序列并用舒尼替尼处理48 h。MTT法检测细胞的增殖,Transwell检测其侵袭,qRT-PCR检测miR-143RNA表达水平,Western blotting检测DNA甲基转移酶3B(DNMT3B)、p-Akt-S473蛋白表达量。结果成功构建稳定、高表达miR-143的人肾癌786-O细胞株,miR-143转染组细胞miR-143表达量增高(P < 0.01)。舒尼替尼作用于786-O细胞48 h的IC50值为6 μmol/L,选取该值作为后续实验用药浓度。786-O细胞经舒尼替尼作用48 h后miR-143表达量升高(P < 0.01)。miR-143组和舒尼替尼组细胞存活率、细胞侵袭数、DNMT3B和p-AktS473蛋白表达量均低于对照组,且高于共同作用组,差异均有统计学意义(P < 0.05~P < 0.01)。结论miR-143可以降低786-O细胞增殖、侵袭能力,这可能与miR-143降低DNMT3B、p-Akt的表达有关。舒尼替尼可能通过上调miR-143水平抑制786-O细胞的增殖与侵袭。

关 键 词:肾细胞癌    舒尼替尼    miR-143    增殖    侵袭
收稿时间:2020-05-20

Effect of regulation of miR-143 by sunitinib on the proliferation and invasion of human renal carcinoma cells
GAO Ying-xin,YING Chong-tao,CUI Di,MEI Chuan-zhong.Effect of regulation of miR-143 by sunitinib on the proliferation and invasion of human renal carcinoma cells[J].Journal of Bengbu Medical College,2021,46(5):566-569.
Authors:GAO Ying-xin  YING Chong-tao  CUI Di  MEI Chuan-zhong
Institution:1.Clinical Testing and Diagnosis Experiment Center, Bengbu Medical College, Bengbu Anhui 2330302.Department of Laboratory Medicine, Bengbu Third People's Hospital, Bengbu Anhui 233000, China3.Department of Biochemistry and Molecular Biology, Bengbu Medical College, Bengbu Anhui 233030
Abstract:ObjectiveTo investigate the role of miR-143 in renal cell carcinoma, the effect of sunitinib on the expression of miR-143 and its association with cell proliferation and invasion.MethodsThe human renal carcinoma 786-O cells were divided into control group, miR-143 group, sunitinib group and co-action group.The negative control sequence was transfected into the cells of control group, the miR-143 sequence was transfected into the cells of miR-143 group, sunitinib group cells were treated with sunitinib for 48h, the co-acting group was transfected miR-143 sequence and treated with sunitinib for 48h.Proliferation and invasion of 786-O cells were detected by MTT and transwell experiment, miR-143 RNA expression was detected by qRT-PCR, DNA methyltrans-ferase3B(DNMT3B).The expressions of p-Akt-S473 protein were detected by Western blotting.ResultsThe human renal cancer 786-O cells with stable and high expression of miR-143 were successfully constructed.The expression of miR-143 was increased in the miR-143 transfected group(P < 0.01).The IC50 value in 786-O cells with the treatment of sunitinib for 48 h was 6 μmol/L, which was selected as the drug concentration in the subsequent experiment.The expression of miR-143 in 786-O cells was increased after the treatment of sunitinib for 48 h(P < 0.01).Cell survival rate, cell invasion number, expressions of DNMT3B and p-Akt-S473 protein in miR-143 and sunitinib group were all lower than control group and higher than co-action group(P < 0.05 to P < 0.01).ConclusionsmiR-143 reduced the proliferation and invasion capacity of 786-O cells, which may be related to the decreased expression of DNMT3B and p-Akt regulated by miR-143.Sunitinib may inhibit the proliferation and invasion of 786-O cells by upregulating miR-143.
Keywords:
本文献已被 万方数据 等数据库收录!
点击此处可从《蚌埠医学院学报》浏览原始摘要信息
点击此处可从《蚌埠医学院学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号